Literature DB >> 20186654

Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.

Sachiko Tsukamoto1, Hideyoshi Yokosawa.   

Abstract

The ubiquitin-proteasome system plays a critical role in selective protein degradation and regulates almost all cellular events such as cell cycle progression, signal transduction, cell death, immune responses, metabolism, protein quality control, development, and neuronal function. The recent approval of bortezomib, a synthetic proteasome inhibitor, for the treatment of relapsed multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and ubiquitinating and deubiquitinating enzymes as well as the delivery system. To date, various synthetic and natural products have been reported to inhibit the components of the ubiquitin-proteasome system. Here, we review natural products targeting the ubiquitin-proteasome system as well as synthetic compounds with potent inhibitory effects. Georg Thieme Verlag KG Stuttgart-New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186654     DOI: 10.1055/s-0029-1240901

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  11 in total

1.  Variabines A and B: new β-carboline alkaloids from the marine sponge Luffariella variabilis.

Authors:  Eriko Sakai; Hikaru Kato; Henki Rotinsulu; Fitje Losung; Remy E P Mangindaan; Nicole J de Voogd; Hideyoshi Yokosawa; Sachiko Tsukamoto
Journal:  J Nat Med       Date:  2013-05-18       Impact factor: 2.343

Review 2.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Min Shen; Sara Schmitt; Daniela Buac; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2013-07-04       Impact factor: 6.902

3.  Identification of a lysine 4-hydroxylase from the glidobactin biosynthesis and evaluation of its biocatalytic potential.

Authors:  Alexander Amatuni; Hans Renata
Journal:  Org Biomol Chem       Date:  2019-02-13       Impact factor: 3.876

Review 4.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

Review 5.  Recent advances in antimultiple myeloma drug development.

Authors:  Nuozhou Wang; Patrick Bartlow; Qin Ouyang; Xiang-Qun Xie
Journal:  Pharm Pat Anal       Date:  2014-05

6.  Development of Proteasome Inhibitors as Therapeutic Drugs.

Authors:  Samuel Troy Pellom; Anil Shanker
Journal:  J Clin Cell Immunol       Date:  2012-03-15

7.  Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system.

Authors:  Jenny Felth; Karolina Lesiak-Mieczkowska; Padraig D'Arcy; Caroline Haglund; Joachim Gullbo; Rolf Larsson; Stig Linder; Lars Bohlin; Mårten Fryknäs; Linda Rickardson
Journal:  Invest New Drugs       Date:  2012-11-20       Impact factor: 3.850

Review 8.  From bortezomib to other inhibitors of the proteasome and beyond.

Authors:  Daniela Buac; Min Shen; Sara Schmitt; Fathima Rani Kona; Rahul Deshmukh; Zhen Zhang; Christine Neslund-Dudas; Bharati Mitra; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Cnidarians as a source of new marine bioactive compounds--an overview of the last decade and future steps for bioprospecting.

Authors:  Joana Rocha; Luisa Peixe; Newton C M Gomes; Ricardo Calado
Journal:  Mar Drugs       Date:  2011-10-10       Impact factor: 6.085

10.  Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.

Authors:  Andrzej Czerwinski; Channa Basava; Miroslawa Dauter; Zbigniew Dauter
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.